Shopping Cart
Remove All
Your shopping cart is currently empty
BAY-069 is an inhibitor. BAY-069 inhibited branched-chain amino acid transaminase 1 (BCAT1) at IC50:31 nM and branched-chain amino acid transaminase 2 (BCAT2) at IC50:153 nM. BAY-069 is a novel (trifluoromethyl) pyrimidine dione chemical probe, which can be used for anticancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $64 | In Stock | In Stock | |
| 2 mg | $93 | In Stock | In Stock | |
| 5 mg | $155 | In Stock | In Stock | |
| 10 mg | $250 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $569 | In Stock | In Stock | |
| 100 mg | $786 | In Stock | In Stock | |
| 200 mg | $1,080 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $170 | In Stock | In Stock |
| Description | BAY-069 is an inhibitor. BAY-069 inhibited branched-chain amino acid transaminase 1 (BCAT1) at IC50:31 nM and branched-chain amino acid transaminase 2 (BCAT2) at IC50:153 nM. BAY-069 is a novel (trifluoromethyl) pyrimidine dione chemical probe, which can be used for anticancer research. |
| Targets&IC50 | BCAT2:153 nM, BCAT1:31 nM |
| In vitro | BAY-069, inhibits the proliferation of U-87 and MDA-MB-231 cells. The compound is tested at concentrations ranging from 70 nM to 50 μM, with a duration of 72 hours. In U-87 cells, the IC50 is determined to be 358 nM, while in MDA-MB-231 cells, the IC50 is 874 nM [1]. |
| In vivo | BAY-069 demonstrates high metabolic stability when incubated with human liver microsomes, with a blood clearance of 0.11 L/h/kg. It also shows moderate metabolic stability when incubated with rat hepatocytes, with a blood clearance of 1.8 L/h/kg. BAY-069 exhibits high permeability through Caco-2 cell monolayers without any signs of efflux [1]. |
| Molecular Weight | 446.81 |
| Formula | C22H14ClF3N2O3 |
| Cas No. | 2639638-66-5 |
| Smiles | O=C1N(C=2C3=C(C(Cl)=C(OC4=C(C)C=CC=C4)C2)C=CC=C3)C(=O)NC(C(F)(F)F)=C1 |
| Relative Density. | 1.450 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (61.55 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.19 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.